Birdwatch Note
2024-11-02 12:53:11 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
« cas fatals » sur les notices de médicaments, y compris les vaccins, est une pratique courante en pharmacovigilance pour informer des ES extrêmement rares mais graves et sous surveillance étroite Le rapport bénéfice/risque est favorable pour les groupes cibles, yc les jeunes https://www.vidal.fr/medicaments/stamaril-pdre-solv-p-susp-inj-en-seringue-preremplie-15514.html https://www.vidal.fr/medicaments/zostavax-pdre-solv-p-susp-inj-en-ser-preremplie-74474.html
Written by 5F44144B6FF1E53568DBC46F3C6B9B7C9FCB0EAE64E7D8691D9B24B398365527
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1852640597661643150
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1852695451624997093
- noteId - 1852695451624997093
- participantId -
- noteAuthorParticipantId - 5F44144B6FF1E53568DBC46F3C6B9B7C9FCB0EAE64E7D8691D9B24B398365527 Participant Details
- createdAtMillis - 1730551991742
- tweetId - 1852640597661643150
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 0
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- « cas fatals » sur les notices de médicaments, y compris les vaccins, est une pratique courante en pharmacovigilance pour informer des ES extrêmement rares mais graves et sous surveillance étroite Le rapport bénéfice/risque est favorable pour les groupes cibles, yc les jeunes https://www.vidal.fr/medicaments/stamaril-pdre-solv-p-susp-inj-en-seringue-preremplie-15514.html https://www.vidal.fr/medicaments/zostavax-pdre-solv-p-susp-inj-en-ser-preremplie-74474.html
Note Ratings
| rated at | rated by | |
| 2024-11-02 16:15:55 -0500 | Rating Details | |
| 2024-11-02 14:13:28 -0500 | Rating Details | |
| 2024-11-02 11:46:48 -0500 | Rating Details | |
| 2024-11-02 09:22:10 -0500 | Rating Details | |
| 2024-11-02 09:14:33 -0500 | Rating Details | |
| 2024-11-04 08:40:20 -0600 | Rating Details | |
| 2024-11-04 02:43:42 -0600 | Rating Details | |
| 2024-11-04 00:25:44 -0600 | Rating Details | |
| 2024-11-03 14:22:55 -0600 | Rating Details | |
| 2024-11-03 13:59:07 -0600 | Rating Details | |
| 2024-11-03 02:49:27 -0600 | Rating Details | |
| 2024-11-02 23:12:14 -0500 | Rating Details | |
| 2024-11-02 12:03:45 -0500 | Rating Details | |
| 2024-11-06 14:40:12 -0600 | Rating Details | |
| 2024-11-05 07:23:40 -0600 | Rating Details | |
| 2024-11-04 04:06:39 -0600 | Rating Details | |
| 2024-11-03 17:34:26 -0600 | Rating Details | |
| 2024-11-03 08:47:38 -0600 | Rating Details | |
| 2024-11-03 07:34:04 -0600 | Rating Details | |
| 2024-11-03 03:24:33 -0600 | Rating Details | |
| 2024-11-03 02:16:46 -0600 | Rating Details | |
| 2024-11-02 16:18:52 -0500 | Rating Details | |
| 2024-11-02 10:21:00 -0500 | Rating Details | |
| 2024-11-02 09:53:27 -0500 | Rating Details | |
| 2024-11-06 23:57:46 -0600 | Rating Details | |
| 2024-11-02 20:10:04 -0500 | Rating Details | |
| 2024-11-02 16:59:32 -0500 | Rating Details | |
| 2024-11-02 15:12:59 -0500 | Rating Details | |
| 2024-11-02 11:43:54 -0500 | Rating Details | |
| 2024-11-02 09:02:33 -0500 | Rating Details |